Identification of mechanisms by which cytisine and estrogen inhibit ER stress and exert neuroprotection in Parkinson's disease
金雀花碱和雌激素抑制 ER 应激并在帕金森病中发挥神经保护作用的机制的鉴定
基本信息
- 批准号:10573172
- 负责人:
- 金额:$ 35.21万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-02-15 至 2025-01-31
- 项目状态:未结题
- 来源:
- 关键词:ATF6 geneAddressAffectAge of OnsetAnimal ModelApomorphineApoptoticAttenuatedBehaviorBehavioralBindingCell DeathCell NucleusCell membraneChronicClinical TrialsComplexCorpus striatum structureCytoplasmDataDevelopmentDopaminergic CellDoseDrug CombinationsDrug KineticsEconomic BurdenEndoplasmic ReticulumEstradiolEstrogen ReceptorsEstrogensExposure toFemaleGaitGenetic TranscriptionGoalsGonadal Steroid HormonesHeat shock proteinsHumanImageIncidenceInjectionsLesionLigandsMediatingMidbrain structureModelingMolecularMolecular ChaperonesMusNeurodegenerative DisordersNeuronsNeuroprotective AgentsNicotinic ReceptorsOutcomeOxidopamineParkinson DiseasePatientsPersonsPharmaceutical PreparationsPhenotypeProcessProtein Export PathwayProteinsRoleRotationSex DifferencesSignal PathwaySignal TransductionSiteStructureTestingToxic effectToxinTransgenic MiceTransgenic OrganismsUp-RegulationWomanWorkXBP1 geneacetylcholine receptor agonistarmclinical translationcytisinedopaminergic neuronendoplasmic reticulum stressexperimental studyfollow-upin vivomalemenmotor symptommouse modelneuron lossneuroprotectionnicotine usenovelpandemic diseasepre-clinicalpreclinical studypreservationpreventprotein activationreceptorsmoking cessationsuccesssymptom treatmenttranscription factortranslational barrier
项目摘要
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, predicted to affect over 12
million people worldwide by 2040. There is no cure for PD and current treatments are merely symptomatic,
which underscores an urgent and unmet need for neuroprotective drugs. One major barrier for the inability to
develop effective and clinically translatable neuroprotective drugs is that no single animal model recapitulates
the complex process that leads to dopaminergic (DA) neuron loss in PD. Therefore, most drugs that succeed in
preclinical animal models fail to work in PD patients. The current proposal addresses this barrier by focusing
on hyperactivated endoplasmic reticulum (ER) stress, which is an established convergent mechanism
downstream of multiple PD-related toxicities. ER stress consists of three signaling arms that culminate in the
translocation of three key proteins – ATF6, XBP1, and CHOP into the nucleus of DA neurons. Moderate
activation of ATF6 and XBP1 is neuroprotective, while chronic, uncontrolled activation of these proteins leads
to DA cell death. By contrast, activation of CHOP invariably causes cell death. Experiments showed that the
nicotinic compound cytisine causes an upregulation of specialized structures called ER exit sites (ERES), and
this is associated with an inhibition of ATF6 and XBP1. Surprisingly, experiments in a 6-hydroxydopamine (6-OHDA)-induced preclinical toxin model of PD showed that cytisine is neuroprotective only in female mice.
Additional preliminary experiments showed that 17-β-estradiol inhibits CHOP expression in DA neurons, which
fits with strong sex-differences observed in the incidence and phenotype of PD, with men being more prone to
developing PD than women. Based on these data, this proposal hypothesizes that cytisine and estrogen exert
neuroprotection in female mice by synergistically inhibiting all three arms (ATF6, XBP1 and CHOP) of
hyperactivated ER stress in DA neurons. Experiments are proposed to determine the extent to which cytisine
requires ERES for exerting neuroprotection by specifically deleting ERES in DA neurons or by using nicotinic
compounds that cannot upregulate ERES. Female mice will be ovariectomized to determine mechanisms by
which specific subtypes of estrogen receptors exert neuroprotection in female mice. On completing
experiments in this proposal, key signaling targets through which cytisine and estrogen mediate
neuroprotective effects will be identified. Success in this proposal will lay groundwork for the long-term goal of
discovering clinically translatable neuroprotective PD drugs that work in both men and women.
帕金森病(PD)是第二常见的神经退行性疾病,预计影响超过12
到2040年,全球将有100万人。帕金森病无法治愈,目前的治疗方法仅仅是对症治疗,
这突出了对神经保护药物的迫切和未满足的需求。一个主要的障碍是,
开发有效的和临床上可转化的神经保护药物的一个重要原因是,没有单一的动物模型可以概括
导致PD中多巴胺能(DA)神经元损失的复杂过程。因此,大多数成功的药物
临床前动物模型未能在PD患者中发挥作用。目前的建议通过以下方式解决这一障碍:
超活化内质网(ER)应激,这是一个既定的收敛机制,
多种PD相关毒性的下游。内质网应激由三个信号传导臂组成,
三种关键蛋白-ATF 6、XBP 1和CHOP易位到DA神经元的核中。中度
ATF 6和XBP 1的激活具有神经保护作用,而这些蛋白质的慢性、不受控制的激活导致
DA细胞死亡相反,CHOP的激活总是导致细胞死亡。实验表明
烟碱化合物金雀花碱引起称为ER出口位点(ERES)的特化结构的上调,
这与ATF 6和XBP 1的抑制有关。令人惊讶的是,在6-羟基多巴胺(6-OHDA)诱导的PD临床前毒素模型中的实验表明,金雀花碱仅在雌性小鼠中具有神经保护作用。
另外的初步实验表明,17-β-雌二醇抑制DA神经元中CHOP的表达,
与PD的发病率和表型中观察到的强烈性别差异相符,男性更倾向于
患帕金森病的人比女性多基于这些数据,该建议假设野靛碱和雌激素发挥作用,
在雌性小鼠中通过协同抑制所有三个臂(ATF 6、XBP 1和CHOP)来进行神经保护。
在DA神经元中过度激活的ER应激。提出实验来确定金雀花碱
需要ERES通过特异性删除DA神经元中的ERES或通过使用烟碱酸来发挥神经保护作用,
不能上调ERES的化合物。将切除雌性小鼠的卵巢,以通过以下方式确定机制:
雌激素受体的哪些特定亚型在雌性小鼠中发挥神经保护作用。于完成
在这项建议的实验中,金雀花碱和雌激素介导的关键信号靶标
将鉴定神经保护作用。这一提案的成功将为实现以下长期目标奠定基础:
发现临床上可转化的神经保护性PD药物,对男性和女性都有效。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rahul Srinivasan其他文献
Rahul Srinivasan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 35.21万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 35.21万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 35.21万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 35.21万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 35.21万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 35.21万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 35.21万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 35.21万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 35.21万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 35.21万 - 项目类别:
Research Grant